Hemogenyx Pharmaceuticals annual asset turnover
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Asset Turnover Growth & History (HEMO)
Hemogenyx Pharmaceuticals's asset turnover was 0.00 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | 0.00 | — |
| 2024 | 2024-12-31 | 0.00 | 0.00 | — |
| 2023 | 2023-12-31 | 0.00 | 0.00 | — |
| 2022 | 2022-12-31 | 0.00 | 0.00 | — |
| 2021 | 2021-12-31 | 0.00 | — | — |
Hemogenyx Pharmaceuticals asset turnover trends
Between the periods ended 2021-12-31 and 2025-12-31, Hemogenyx Pharmaceuticals's asset turnover increased from 0.00 to 0.00, a change of 0.00.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
